Canada's Centre of Excellence for the Prevention of Organ Failure – also called the PROOF Centre – has partnered with Origene Technologies on blood-based protein assays for monitoring heart and kidney transplantation.
The agreement covers a multi-year project that aims to provide monitoring and predictive blood tests for heart and kidney transplant patients. Origene will use its experience in monoclonal antibody production and Luminex multiplex assay development to build and implement diagnostic assays for transplant care, the company said in a statement.
It added that this was "the first announced clinical development project" using Origene's UltraMAB antibodies – a recently released line of antibodies that the company said are "validated for specificity and low cross-reactivity."
According to a recent study by the PROOF Centre, implementation of blood-based protein tests for organ rejection could save British Columbia up to C$700,000 (US$700,000) over five years.